

Practitioner's Docket No.: 1996.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : **10/802,000** Confirmation No. **2824**
Applicant : **Thomas N. Thomas**
Filed: : **03/16/2004**
TC/A.U. : **1614**
Examiner : **Phyllis G. Spivack**
Docket No. : **1996.01**
Customer No. : **21,901**
For : **Compositions and Methods to Prevent Toxicity of Inflammatory Agents and Enhance their Efficacy**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner Spivack:

Applicant responds to the nonfinal Examiner's action mailed April 14, 2011, having a shortened statutory period for response set to expire May 14, 2011 as follows:

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

Applicant elects to prosecute aspirin as the anti-inflammatory drug. Applicant reserves the right to rejoinder, should generic claims be found allowable. This election is made without traverse.

SUMMARY OF EXAMINER INTERVIEW

Applicant's representative, Robert Varkonyi, spoke with Examiner Spivack on April 25, 2011 to discuss the specificity required in responding to the species election. Examiner Spivack stated that the election must require a specific compound. Applicant thanks Examiner Spivack for her time and assistance in clarifying this matter.